| Literature DB >> 35200709 |
Changhu Xiao1, Yuan Guo1,2,3, Kaixuan Zhao1, Sha Liu1, Nongyue He1, Yi He2, Shuhong Guo2, Zhu Chen1.
Abstract
(1) Background: Patients with acute myocardial infarction (AMI) still experience many major adverse cardiovascular events (MACEs), including myocardial infarction, heart failure, kidney failure, coronary events, cerebrovascular events, and death. This retrospective study aims to assess the prognostic value of machine learning (ML) for the prediction of MACEs. (2)Entities:
Keywords: acute myocardial infarction; logistic regression analysis; machine learning; major adverse cardiovascular events
Year: 2022 PMID: 35200709 PMCID: PMC8880640 DOI: 10.3390/jcdd9020056
Source DB: PubMed Journal: J Cardiovasc Dev Dis ISSN: 2308-3425
Figure 1Study flowchart. AMI, acute myocardial infarction; PCI, percutaneous coronary intervention.
Patients’ characteristics of included subjects.
| Characteristic | All ( | Non-MACEs ( | MACEs ( | |
|---|---|---|---|---|
| Age (y) | 62.95 ± 12.98 | 61.32 ± 12.32 | 66.65 ± 13.71 | <0.0001 |
| Male (%) | 317 (77.7%) | 223 (78.8%) | 94 (75.2%) | 0.421 |
| Follow-up time (d) | 516.45 ± 137.82 | 509.88 ± 139.37 | 531.30 ± 133.61 | 0.148 |
| Coronary lesion vessels (num) | 2.14 ± 1.00 | 2.08 ± 1.00 | 2.27 ± 0.98 | 0.081 |
| Number of stents implanted | 1.79 ± 1.06 | 1.74 ± 1.08 | 1.90 ± 1.00 | 0.145 |
| Electrocardiogram (%) | 258 (63.2%) | 179 (63.3%) | 79 (63.2%) | 0.992 |
| Killip classification (I:II:III:IV) | <0.0001 | |||
| I | 266 (65.2%) | 204 (72.1%) | 62 (49.6%) | |
| II | 82 (20.1%) | 52 (18.4%) | 30 (24.0%) | |
| III | 26 (6.4%) | 13 (4.6%) | 13 (10.4%) | |
| IV | 34 (8.3%) | 14 (4.9%) | 20 (16%) | |
| Cholesterol (mmol/L) | 4.44 ± 1.04 | 4.56 ± 1.07 | 4.16 ± 0.93 | <0.0001 |
| Low density lipoprotein (mmol/L) | 2.68 ± 0.87 | 2.76 ± 0.87 | 2.49 ± 0.83 | 0.004 |
| C-reactive protein (mg/L) | 18.14 ± 19.97 | 17.02 ± 19.49 | 20.70 ± 20.89 | 0.086 |
| Left ventricular diameter (mm) | 47.18 ± 5.85 | 46.80 ± 5.39 | 48.04 ± 6.73 | 0.049 |
| Left ventricular ejection fraction (%) | 0.52 ± 0.10 | 0.53 ± 0.09 | 0.50 ± 0.11 | 0.002 |
| Creatinine (µmol/L) | 92.59 ± 46.70 | 85.63 ± 38.40 | 108.35 ± 58.68 | <0.0001 |
| Uric acid (µmol/L) | 349.94 ± 101.27 | 337.86 ± 98.94 | 377.29 ± 101.54 | 2.64 × 10−4 |
| Glucose (mmol/L) | 8.78 ± 5.14 | 8.53 ± 5.13 | 9.36 ± 5.13 | 0.131 |
| White blood cells (109/L) | 10.46 ± 4.29 | 10.21 ± 4.00 | 11.02 ± 4.85 | 0.103 |
| Neutrophils (109/L) | 8.07 ± 4.11 | 7.89 ± 4.03 | 8.49 ± 4.28 | 0.168 |
| Hypertension (%) | 228 (55.9%) | 153 (54.1%) | 75 (60%) | 0.206 |
| Cigarettes (%) | 199 (48.8%) | 145 (51.2%) | 54 (43.2%) | 0.134 |
| Past medical history (%) | 132 (32.4%) | 83 (29.3%) | 49 (39.2%) | 0.049 |
| Diabetes (%) | 101 (24.8%) | 66 (23.3%) | 35 (28%) | 0.313 |
| Drug compliance (%) | 339 (83.4%) | 249 (88.0%) | 90 (72%) | <0.0001 |
| Revascularization time (min) | 4885 ± 11,126 | 4736 ± 10,264 | 5224 ± 12,917 | 0.683 |
| Number of diseased vessels | 2.14 ± 1.00 | 2.09 ± 1.01 | 2.26 ± 0.98 | 0.100 |
The result of logistic regression analysis.
| Characteristic | OR | 95% | |
|---|---|---|---|
| Killip classification | 0.001 | ||
| 2.849 | (1.181–6.873) | 0.02 | |
| 4.386 | (1.943–9.904) | <0.0001 | |
| Drug compliance | 3.06 | (1.721–5.438) | <0.0001 |
| Age (per year) | 1.025 | (1.006–1.044) | 0.01 |
| Creatinine (1 µmol/L) | 1.007 | (1.002, 1.012) | 0.004 |
| Cholesterol (1 mmol/L) | 0.708 | (0.556–0.903) | 0.005 |
Figure 2The statistical analysis for independent predictors of major adverse cardiovascular events. (A) The comparison of major adverse cardiovascular event (MACE) rates in different grades of the Killip classification. (B) The comparison of MACE rates between irregular and regular groups of drug compliance. Analysis of differences for the distribution of age (C) and the levels of creatinine (D) and cholesterol (E) between the Non-MACE group and the MACE group. A significant difference was set at p < 0.05.
Comparison of performance between various models in the validation dataset.
| Classifier | AUC, Mean (95%CI) | Accuracy, Mean (95%CI) | F1-Score, Mean (95%CI) |
|---|---|---|---|
| Logistic regression | 0.717 (0.692–0.743) | 0.721 (0.648–0.795) | 0.565 (0.483–0.646) |
| Decision tree | 0.664 (0.488–0.840) | 0.644 (0.463–0.825) | 0.532 (0.374–0.690) |
| Naive Bayes | 0.733 (0.650–0.718) | 0.742 (0.681–0.803) | 0.503 (0.358–0.648) |
| Support vector machine | 0.717 (0.687–0.746) | 0.725 (0.639–0.811) | 0.570 (0.483–0.656) |
| Random forest | 0. 749 (0.644–0.853) | 0.734 (0.647–0.820) | 0.480 (0.358–0.602) |
| Gradient boosting | 0.737 (0.637–0.838) | 0.729 (0.628–0.831) | 0.453 (0.206–0.701) |
| Multilayer perceptron | 0.663 (0.532–0.794) | 0.697 (0.599–0.795) | 0.103 (−0.162–0.368) |
Figure 3The comparison of generalization ability among the developed models. (A) The area under the curve for all models used in the testing dataset. (B) The evaluation of accuracy rate and F1-score among the used models in the testing dataset. DT, decision tree; LR, logistic regression; NB, Naive Bayes; SVM, support vector machine; GB, gradient boosting; MLP, multilayer perceptron.
Figure 4Calibration plots for the developed models.
Figure 5Kaplan–Meier analysis for major adverse cardiovascular events. Kaplan–Meier curve for MACEs in DT (A), LR (B), NB (C), SVM (D), RDF (E), GB (F), and MLP (G) models: subgroup1—patients who were predicted to show a good prognosis by the corresponding model; subgroup2—patients who were predicted to show a bad prognosis by the corresponding model. Kaplan–Meier curve for MACEs when the study population in the testing dataset was randomly partitioned into two equal groups (H) and when the whole study population in the testing dataset was included (I).